… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… it will present preclinical data for its proprietary Axiomer™ RNA editing technology platform and its AX-0810 … a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the … has served on ProQR’s Supervisory Board since 2014. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced … will then be available for approximately 30 days. About Axiomer ™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer ™ , which could potentially yield a new class of …
… ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its …
… trial in 2022. RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and shown … will develop selected genetic eye disease targets with Axiomer ® , and will provide further guidance on this in H2 …
… with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial … 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & … the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur